Merck’s Tulisokibart Achieves Remission Endpoint in Phase 3 Ulcerative Colitis Trial
MRK•Merck’s anti-TL1A antibody tulisokibart met its primary endpoint of clinical remission at week 12 in a global Phase 3 ulcerative colitis trial involving moderate-to-severe patients. This positive readout strengthens Merck’s late-stage pipeline as a non-oncology growth driver ahead of Keytruda’s patent expiry.
1. Trial Design and Results
The global Phase 3 study of tulisokibart enrolled moderate-to-severe ulcerative colitis patients and assessed clinical remission at week 12 as its primary endpoint. The antibody achieved statistically significant remission rates over placebo, marking its first late-stage success in inflammatory bowel disease.
2. Regulatory Next Steps
Merck plans to compile the Phase 3 data for submission to health authorities pending analysis of safety and secondary endpoints. If filings proceed on schedule, approval could follow within 12–18 months, targeting the multi-billion-dollar ulcerative colitis market.
3. Pipeline Impact
This positive readout adds a high-value immunology asset to Merck’s portfolio, reducing reliance on oncology revenues like Keytruda. Success with tulisokibart underscores the company’s strategy to drive growth through diversified late-stage programs.
